<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03603314</url>
  </required_header>
  <id_info>
    <org_study_id>SENS 401-201</org_study_id>
    <nct_id>NCT03603314</nct_id>
  </id_info>
  <brief_title>Efficacy of SENS 401 in Subjects With Severe or Profound Sudden Sensorineural Hearing Loss</brief_title>
  <acronym>AUDIBLE-S</acronym>
  <official_title>A Two-part, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of SENS-401 in Subjects With Severe or Profound Sudden Sensorineural Hearing Loss</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sensorion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sensorion</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective of the study is to assess the efficacy of SENS-401 on hearing loss in
      comparison to placebo at the end of the 4-week treatment period
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will receive the study drug (SENS-401 or placebo) in the form of tablets by mouth,
      twice a day (3 tablets in the morning and 3 tablets in the evening), during the first 4 weeks
      after randomization.

      SENS-401 is an investigational medicinal product. It belongs to a family of drugs known as &quot;5
      HT3 antagonist&quot;.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 15, 2019</start_date>
  <completion_date type="Anticipated">August 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in pure tone audiometry PTA (dB)</measure>
    <time_frame>28 days</time_frame>
    <description>Change in pure tone audiometry PTA (dB) in affected ear from baseline to the end of treatment visit</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">458</enrollment>
  <condition>Severe Sudden Sensorineural Hearing Loss</condition>
  <arm_group>
    <arm_group_label>29 mg dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive the study drug (SENS-401) in the form of tablets by mouth, twice a day, during the first 4 weeks after randomization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>43.5 mg dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive the study drug (SENS-401) in the form of tablets by mouth, twice a day, during the first 4 weeks after randomization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo oral tablet</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive the study drug (placebo) in the form of tablets by mouth, twice a day, during the first 4 weeks after randomization.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SENS-401</intervention_name>
    <description>29 mg dose group: tablets of 14.5 mg, oral route, by mouth, twice a day, during 4 weeks</description>
    <arm_group_label>29 mg dose group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>placebo, oral route, by mouth, twice a day, during 4 weeks</description>
    <arm_group_label>placebo oral tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SENS-401</intervention_name>
    <description>43.5 mg dose groupe: tablets of 14.5 mg, oral route, by mouth, twice a day, during 4 weeks</description>
    <arm_group_label>43.5 mg dose group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female

          -  Over 18 years old

          -  Patients with unilateral sudden sensorineural hearing loss

        Exclusion Criteria:

          -  Bilateral hearing loss

          -  History of Meniere's disease, autoimmune hearing loss, radiation-induced hearing loss,
             acoustic neuroma.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Géraldine HONNET, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sensorion</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sandrine MEUNIER, MSc</last_name>
    <phone>+33(0)786676542</phone>
    <email>sandrine.meunier@sensorion-pharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Judith LAREDO, PhD</last_name>
    <phone>+33(0)663737108</phone>
    <email>judith.laredoi@sensorion-pharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Lariboisière</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlotte Hautefort, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>July 5, 2018</study_first_submitted>
  <study_first_submitted_qc>July 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2018</study_first_posted>
  <last_update_submitted>May 15, 2020</last_update_submitted>
  <last_update_submitted_qc>May 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hearing Loss</mesh_term>
    <mesh_term>Deafness</mesh_term>
    <mesh_term>Hearing Loss, Sensorineural</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

